Okamura J, Letarte M, Gelfand E W
J Clin Immunol. 1984 May;4(3):228-34. doi: 10.1007/BF00914970.
The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces a variety of phenotypic changes on normal and malignant cells. In chronic and acute lymphocytic leukemia we have observed a marked augmentation in mixed lymphocyte reaction stimulatory capacity (MLRs) following pretreatment of leukemia blasts with TPA. We have now characterized the effects of TPA on MLRs utilizing the non-T, non-B lymphoblastic leukemia-cell line, HOON. Following pretreatment with TPA (optimal concentration, 1.6 X 10(-10) M), but not with other phorbol esters, there was a marked increase in MLRs, particularly at lower stimulator-cell concentrations. This effect was maximal following a 44-hr preincubation period and the enhancement in MLRs was not accompanied by changes in levels of Ia expression. This cell line provides a model for determining the molecular basis for the TPA-induced augmentation of stimulatory capacity in the mixed lymphocyte reaction.
肿瘤促进剂12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯（TPA）可诱导正常细胞和恶性细胞发生多种表型变化。在慢性和急性淋巴细胞白血病中，我们观察到用TPA预处理白血病原始细胞后，混合淋巴细胞反应刺激能力（MLR）显著增强。我们现在利用非T、非B淋巴细胞白血病细胞系HOON来表征TPA对MLR的影响。用TPA（最佳浓度为1.6×10⁻¹⁰ M）预处理后，但用其他佛波酯预处理则无此效果，MLR显著增加，尤其是在较低刺激细胞浓度时。在44小时的预温育期后，这种效应达到最大，并且MLR的增强并未伴随Ia表达水平的变化。该细胞系为确定TPA诱导混合淋巴细胞反应中刺激能力增强的分子基础提供了一个模型。
